期刊
HUMAN IMMUNOLOGY
卷 70, 期 8, 页码 631-635出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2009.06.006
关键词
-
类别
At the North Italy Transplant Program (NITp) Reference Center, which is responsible for pre- and posttransplant immunological evaluation and organ allocation, the sera of patients who enter the kidney waiting list are analyzed with complement dependent cytotoxicity (CDC) and a microbead array technique (Luminex). At present, the NITp Waiting list includes 2543 patients. The rate of patients with a percentage panel-reactive antibody (PRA) >= 30 with CDC is about 8%; among them, 1% exhibits a %PRA >= 85. Furthermore, 14% of patients have antibodies detectable only with Luminex. The overall 5-year graft survival in the period 1997-2008 is 85%, whereas that of individuals with a CDC %PRA >= 30 is 80.1% (p = 0.0355). A retrospective analysis oil the effect Of Luminex-detected anti-human leukocyte antigen (HLA) antibodies has Suggested that there is a posttransplant immunological response in Luminex-positive patients that call slowly produce kidney damage. Here we present the NITp current policy for the screening and identification of anti-HLA antibodies in relation to kidney allocation algorithm and the authors' view oil some aspects of discussion. (C) 2009 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据